Daily Ards Research Analysis
Analyzed 5 papers and selected 3 impactful papers.
Summary
An international pragmatic RCT found that sugammadex modestly reduced postoperative pulmonary complications compared to neostigmine, chiefly driven by fewer atelectasis events. A NICU retrospective cohort linked ventilation duration to gestational age and birth weight. A detailed ARDS case secondary to miliary tuberculosis illustrates potential benefit of high-dose glucocorticoids with careful management of noninvasive ventilation-related barotrauma.
Research Themes
- Perioperative pulmonary complications and neuromuscular blockade reversal
- Determinants of neonatal mechanical ventilation duration
- Treatment strategies and ventilatory risks in TB-associated ARDS
Selected Articles
1. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial.
In 3,498 adults undergoing major abdominal or thoracic surgery, sugammadex reduced the composite of postoperative pulmonary complications or death versus neostigmine (19.0% vs 21.5%; RR 0.88, 95% CI 0.77–1.00; p=0.049). The effect was mainly due to fewer atelectasis events; pneumonia and mortality were similar, and no treatment-related adverse events were identified.
Impact: This large, pragmatic, masked-outcome RCT provides high-level evidence that choice of neuromuscular blockade reversal agent can modestly influence clinically relevant postoperative pulmonary outcomes.
Clinical Implications: Consider sugammadex as a first-line agent for reversal of aminosteroid-induced neuromuscular blockade in abdominal/thoracic surgeries, especially in patients at risk of pulmonary complications; weigh benefits against cost as the absolute risk reduction is modest.
Key Findings
- Composite postoperative pulmonary complications or death: 19.0% (sugammadex) vs 21.5% (neostigmine); RR 0.88 (95% CI 0.77–1.00); p=0.049
- Atelectasis reduced: 18.4% vs 21.1%; RR 0.86 (95% CI 0.76–0.99); p=0.030
- No difference in pneumonia (2.1% vs 2.2%) or mortality (0.1% vs 0.1%); no treatment-related adverse events
- ARDS was not reported among outcomes; dosing was pragmatic at clinician discretion
Methodological Strengths
- Pragmatic, multicentre, randomised, controlled design with masked outcome assessment
- Large intention-to-treat sample with prespecified registration and stratified randomisation
Limitations
- Effect size was modest and primarily driven by atelectasis of uncertain clinical significance
- Open-label to treating clinicians with dose discretion; generalisability beyond included procedures and populations may be limited
Future Directions: Assess cost-effectiveness, identify high-risk subgroups who derive greater benefit, and standardise neuromuscular monitoring and dosing strategies in future trials.
BACKGROUND: Sugammadex and neostigmine are used to reverse aminosteroid neuromuscular-blocking drugs at the end of surgery. We aimed to determine whether reversal of neuromuscular blockade with sugammadex reduces the incidence of postoperative pulmonary complications or death compared with neostigmine. METHODS: We conducted a pragmatic, international, multicentre, randomised, controlled, phase 4 trial involving 44 hospitals in Australia, Aotearoa New Zealand, and Hong Kong. Eligible patients were adults (aged ≥40 years) who were having abdominal or thoracic surgery under general anaesthesia and lasting at least 2 h, with an expected postoperative hospital stay of 1 night or longer. Patients were randomly assigned (1:1) to sugammadex or neostigmine, administered intravenously in doses chosen by the attending anaesthesiologist, for reversal of rocuronium-induced or vecuronium-induced neuromuscular blockade at the end of surgery. Randomisation was done via a web-based service, in random permuted blocks of varying sizes of 2 and 4 and stratified by centre. Patients, research staff who were responsible for outcome assessments, and members of the endpoint adjudication committee were masked to group assignment. The primary outcome was postoperative pulmonary complications or death up to hospital discharge (or postoperative day 7 if still in hospital). The trial is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12623000394640) and is closed to accrual.
2. Association between mechanical ventilation duration and maternal-neonatal factors in critically ill neonates: A retrospective study.
In 319 ventilated NICU neonates, total ventilation time had a median of 133 hours, with all receiving invasive ventilation (median 48 hours) and most requiring subsequent noninvasive support. Ventilation duration was inversely associated with gestational age and influenced by birth weight, suggesting perinatal factors critically shape respiratory trajectory.
Impact: Identifies modifiable and non-modifiable perinatal determinants of ventilation burden in critically ill neonates, informing risk stratification and resource planning.
Clinical Implications: Use gestational age and birth weight to anticipate ventilation needs, counsel families, and tailor weaning strategies; consider diagnosis-specific pathways (e.g., RDS vs non-RDS) when planning respiratory support.
Key Findings
- Median total mechanical ventilation duration: 133 hours (IQR 146)
- All neonates received invasive ventilation (median 48 hours, IQR 58); 83.7% required subsequent noninvasive support
- Ventilation duration was negatively correlated with gestational age and influenced by birth weight
Methodological Strengths
- Moderate sample size with detailed perinatal and physiologic data collection
- Subgroup analyses contrasting RDS and non-RDS groups
Limitations
- Single-centre retrospective design with potential residual confounding
- Limited reporting of illness severity adjustment and absence of long-term outcomes
Future Directions: Prospective multicentre validation and development of prediction models integrating gestational age, birth weight, and diagnosis to optimise ventilation strategies.
OBJECTIVE: To examine the associations between neonatal-maternal characteristics and mechanical ventilation duration in critically ill neonates, and to explore differences between respiratory distress syndrome (RDS) and non-RDS subgroups. METHODS: This retrospective study included 319 neonates who required mechanical ventilation in the neonatal intensive care unit of our hospital between 1 January 2022 and 31 December 2024. Data on neonatal demographics, Apgar scores, initial arterial blood gas parameters and maternal characteristics, including age, delivery mode and comorbidities, were collected. The primary outcome was total ventilation duration. Correlation and subgroup analyses were performed. RESULTS: The median duration of total mechanical ventilation (invasive + non-invasive) was 133.0 (interquartile range (IQR): 146.0) h. All neonates received invasive mechanical ventilation with a median duration of 48.0 (IQR: 58.0) h, and 83.7% subsequently required non-invasive ventilation support. Ventilation duration was negatively correlated with gestational age ( CONCLUSIONS: Neonatal factors, especially gestational age and birth weight, critically impact ventilation duration in critically ill neonates. Tailored respiratory management addressing diagnosis and key perinatal factors (gestational age, birth weight) may improve outcomes.
3. Successful treatment by high dose glucocorticoid of miliary tuberculosis complicated with acute respiratory distress syndrome: a case report.
High-dose methylprednisolone (160 mg/day) plus noninvasive positive pressure ventilation initially improved ARDS due to miliary tuberculosis, followed by barotrauma (pneumothorax, subcutaneous/mediastinal emphysema) and suspected DIC after 8 days. After cessation of NIPPV and supportive management, the patient recovered fully after one year of antituberculous therapy.
Impact: Provides granular, biopsy-confirmed clinical course highlighting both potential benefit of adjunctive high-dose glucocorticoids and the significant barotrauma risks of prolonged NIPPV in TB-associated ARDS.
Clinical Implications: When managing TB-associated ARDS, consider adjunctive corticosteroids alongside antituberculous therapy and use NIPPV cautiously with vigilant monitoring for barotrauma and coagulopathy.
Key Findings
- Biopsy-confirmed miliary TB with ARDS despite negative sputum smears; pleural ADA/IFN-γ supported TB pleurisy
- High-dose methylprednisolone (160 mg/day) with NIPPV led to early improvement
- Prolonged NIPPV resulted in barotrauma (pneumothorax, subcutaneous and mediastinal emphysema) and suspected DIC
- Complete clinical and radiological recovery after one year of antituberculous therapy with supportive care
Methodological Strengths
- Histopathological confirmation with acid-fast staining and longitudinal follow-up to 1 year
- Detailed imaging, laboratory, and ventilatory management timeline
Limitations
- Single-patient case limits generalisability and causal inference
- Concurrent therapies (antituberculous drugs, supportive measures) confound attribution of benefit to steroids
Future Directions: Prospective studies to define optimal steroid regimens and ventilatory strategies in TB-associated ARDS, with monitoring for barotrauma and coagulopathy.
A 25-year-old previously healthy man presented with a productive cough for 2 months and progressive dyspnea for 1 week. He did not respond to initial anti-infective treatment at a local hospital. Chest computed tomography (CT) demonstrated diffuse miliary nodules, ground-glass opacities throughout both lungs, and bilateral pleural effusion (more prominent on the right). Laboratory tests revealed type I respiratory failure, elevated inflammatory markers, hyponatremia, hypoproteinemia, and raised tumor markers (NSE, CYFRA21-1, SCC, CA125). Sputum acid-fast bacilli smears were negative, but pleural fluid analysis showed elevated adenosine deaminase and interferon-gamma, suggestive of tuberculous pleurisy. Percutaneous lung biopsy confirmed epithelioid granulomas with positive acid-fast staining, establishing the diagnosis of miliary tuberculosis, tuberculous pleurisy, severe pulmonary infection, and acute respiratory distress syndrome (ARDS). Anti-tuberculosis therapy was withheld initially due to elevated liver enzymes and was initiated once liver function normalized.